CClinicalTrials.gg
RecruitingNCT06206226OHDC-DCUpdated Sep 29, 2026

The Oh Happy Day Class - Digital Connections (OHDC-DC): A Pilot Study

An interventional study of OHDC-DC in Depression, Depressive Disorder and Depressive Symptoms, sponsored by University of Wisconsin, Madison. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by University of Wisconsin, Madison · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to see if a mobile phone app can deliver depression treatment to African Americans who are depressed. The main question it aims to answer is if this treatment is effective in reducing symptoms of depression.

Participants will attend six 90-minute weekly classes via an app on their phone, and will be asked to complete surveys every week. Participants can expect to be in the study for four months.

Read the detailed description

The Oh Happy Day Class-Digital Connections (OHDC-DC) is designed for African American adults experiencing clinical depression (CD). OHDC originally comprised of 13 treatment modules focused on culturally relevant strategies to increase knowledge of depression and healthy coping behaviors aimed at reducing symptoms of clinical depression and improving health outcomes.

The Oh Happy Day Class-Digital Connections (OHDC-DC) comprise of 5 core elements of the OHDC-DC:

  1. 90-minute-weekly cognitive behavioral psycho-education classes over a 6-week period.
  2. Six classes will be offered and facilitated online in the computerized OHDC-DC.
  3. Participants will be encouraged to stay engaged between classes by digitally connecting on the app with the class content. On the app they will receive reminders and messages from staff and participants to stay digitally connected and engaged.
  4. Embedded in the classes and content is psychoeducation with an emphasis on educating participants about depression, raising awareness of mental illness with the goal of normalizing it and reducing stigma, and increasing healthy coping behaviors, and.
  5. The intervention will be delivered by a licensed mental health clinician.
02

Conditions studied

  • Depression
  • Depressive Disorder
  • Depressive Symptoms

Keywords

  • African American
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • African-American
  • Age 18 and older
  • Experiencing depression (as evidenced by a score of 5 or higher on the PHQ-9)
  • Own a mobile phone

Exclusion criteria

Exclusion Criteria:

  • Individuals who are currently receiving psychotherapy
  • Individuals who are presently experiencing suicidal ideation
  • Individuals who started psychotropic medication less than three months prior to the start of the OHDC will be excluded from the study
  • Participants scoring 25 or higher on the PHQ-9 will be screened out
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    Oh Happy Day Class-Digital Connections (OHDC-DC)

    Behavioral: OHDC-DC

Interventions

  • BehavioralOHDC-DC

    90-minute-weekly cognitive behavioral psycho-education classes using a mobile phone app over a 6-week period

05

What researchers measure

Primary outcomes

  1. Change in Personal Health Questionnaire Depression Scale score

    Using the 8 item Personal Health Questionnaire Depression Scale (PHQ-8), participants will rate how much they have been bothered by symptoms on a scale of 0-3 with a possible range of 0 to 24. Higher scores indicate greater degree of depression.

    Time frame: Baseline to one month post-intervention (approximately 12 weeks)

  2. Change in Generalized Anxiety Disorder 7-item (GAD-7) score

    Using the GAD-7 score, participants will rate how much they have been bothered by symptoms on a scale of 0-3 with a possible range of 0 to 24. Higher scores indicate greater degree of anxiety.

    Time frame: Baseline to one month post-intervention (approximately 12 weeks)

  3. Change in Quick Inventory of Depressive Symptomatology (QIDS)

    Using the 16-item QIDS, participants will rate how much they have been bothered by symptoms on a scale of 0-3 with a possible range of 0 to 27. Higher scores indicate greater degree of depression.

    Time frame: Baseline to one month post-intervention (approximately 12 weeks)

  4. Satisfaction with intervention

    Participants will rate their satisfaction with the intervention by answering a 9-item questionnaire with a scale of 1-7 (1= none of the time, 7= all of the time). Higher scores indicate greater satisfaction with the intervention.

    Time frame: 12 weeks

06

Study locations

1 of 1 sites recruiting
  • University of Wisconsin
    Madison, Wisconsin 53705, United States
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06206226
Lead sponsor
University of Wisconsin, Madison
Responsible party
Sponsor
First posted
Jan 16, 2024
Start date
Oct 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Shari Barlow
Contact
shari.barlow@fammed.wisc.edu
608-265-4348
Earlise Ward, PhD
principal investigator · University of Wisconsin, Madison

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion